{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:43:15Z","timestamp":1790980995259,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.leukres.2005.04.003","type":"journal-article","created":{"date-parts":[[2005,4,28]],"date-time":"2005-04-28T13:13:57Z","timestamp":1114694037000},"page":"1259-1262","source":"Crossref","is-referenced-by-count":31,"title":["Vitamin D2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome"],"prefix":"10.1016","volume":"29","author":[{"given":"H. Phillip","family":"Koeffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noune","family":"Aslanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"O\u2019Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2005.04.003_bib1","article-title":"Myelodysplastic syndromes II","volume":"vol. 33","author":"Miescher","year":"1996"},{"key":"10.1016\/j.leukres.2005.04.003_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood.V62.4.709.709","article-title":"Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications","volume":"62","author":"Koeffler","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.003_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(84)92676-X","article-title":"Treatment of advanced myelodysplastic syndrome with alfacalcidol","volume":"2","author":"Mehta","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2005.04.003_bib4","first-page":"1399","article-title":"1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells","volume":"69","author":"Koeffler","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.leukres.2005.04.003_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.2830230212","article-title":"Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3","volume":"23","author":"Richard","year":"1986","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.04.003_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.2830380112","article-title":"The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes","volume":"38","author":"Motomura","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2005.04.003_bib7","doi-asserted-by":"crossref","unstructured":"O\u2019Kelly J, Morosetti R, Koeffler HP. Vitamin D and hematological malignancy. In: Feldman D, Glorieux FH, Pike JW, editors. Vitamin D, 2nd ed. Academic Press, San Diego.","DOI":"10.1016\/B978-012252687-9\/50100-5"},{"key":"10.1016\/j.leukres.2005.04.003_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-3-642-55580-0_23","article-title":"Vitamin D analogs and breast cancer","volume":"164","author":"O\u2019Kelly","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.leukres.2005.04.003_bib9","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2005.04.003_bib10","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1 25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.leukres.2005.04.003_bib11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.leukres.2005.04.003_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.04.003_bib13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jnci\/95.12.896","article-title":"Non-calcemic vitamin D2 analog, 19-nor-125(OH)2D2: antitumor activity against leukemia, myeloma and colon cancer","volume":"95","author":"Kumagai","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2005.04.003_bib14","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.003_bib15","first-page":"901","article-title":"The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer","volume":"6","author":"Chen","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2005.04.003_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00432-002-0405-7","article-title":"19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines","volume":"129","author":"Molnar","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.leukres.2005.04.003_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1007089632152","article-title":"Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells","volume":"208","author":"Torres","year":"2000","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.leukres.2005.04.003_bib18","first-page":"1925","article-title":"Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D","volume":"21","author":"Siwinska","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.leukres.2005.04.003_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1006123819675","article-title":"Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo","volume":"53","author":"Koshizuka","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.leukres.2005.04.003_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1067\/mcp.2002.129305","article-title":"Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel","volume":"72","author":"Muindi","year":"2002","journal-title":"Clin Pharmacol Ther"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605001621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605001621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T03:57:25Z","timestamp":1625889445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212605001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0145212605001621"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.04.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}